RE:Was that implode you meant?canon12345 wrote: This company has had its revenue cut in half in North America. Down $60 million overall Quarter to Quarter. Loss per share form ($.09) to ($1.54). The only positive is a bunch of talk of new products that are going to COMPETE in new markets. Yes after the latest disaster here I see how well this Company competes. Have no idea how they think of this as a turnaround, more like a continuing disaster!
Well said. The new products are fiction. On the conference call they said they launched one product this quarter. Didn't even announce it in a PR as it would be obvious its a repack.
Would not answer questions directly on the conference call. Whey Meihm asked if they pay 1% or 7% to the voluntary scheme Graham would not say. Does he not know that this is public information? I don't have much use for Douglas Meihm, but when he asked "Why not disclose this value.. this can make the difference for beta in 2018 for the company ..:" and Graham refused to answer then the writing was on the wall for this company. The international segment was what they said would hold revenues up, however from this earnings it now appears that they are crashing as well (shows down 8% this quarter without the pricing bill in full effect) And what did they blame it on? Competition and foreign exchange! Well, yeah Concordia - your drugs are old and being replaced with newer more innovative durgs and your price gouging model doesn't work any more. So why are investors wondering why this company is headed for zero?